Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (5639)	2/24/1998 7:03:00 AM
From: blankmind	Respond to of 23519

- Good analysis of treatments. MUSE definitely has the edge against the competition in many respects. - Also, vivus could still possibly get caught up in the drug industry merger game. biz.yahoo.com - If nothing else, vivus's $90+ mill cash reserve makes it somewhat attractive. And I guess the potential to earn $3 or $4 a share won't hurt. Out.

To: EyeDrMike who wrote (5639)	2/24/1998 8:40:00 AM
From: Edderd	Read Replies (2) \| Respond to of 23519

Mike, Those are nice observations and categories of patients but not reality. Most of the time the doc is not going to be able to make that critical determination that this patient cannot be treated with Viagra. How would he determine this? We don't have any contraindications listed yet and it seems to be quite safe on preliminary reports. it's discussed at every meeting. Scenario #2 is however the saving grace of MUSE. It will probably take 4 to 8 doses before the patients will give it up and look elsewhere. My guess is 1 to 2 months. Don't forget there is a huge placebo class in this group who will swear by Viagra and boost it's image for quite a while. All IMHO Ed